---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-139121"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:12:42.661617+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs

## Summary
- CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.
- Severance compensation consistent with service agreement terms (Exhibits 10.24, 10.25 to 2023 10-K).
- No replacement appointed; company restructures clinical leadership without a CMO.

## SEC filing metadata
- accession: 0000950170-24-139121
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024139121/0000950170-24-139121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024139121/sndx-20241220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-139121
- JSON: https://secwatch.observer/filing/0000950170-24-139121.json
- Plain text: https://secwatch.observer/filing/0000950170-24-139121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.